Interim results for the six months to 30 June 2026

Summary by AI BETAClose X

Arecor Therapeutics plc reported interim results for the six months ended June 30, 2026, with revenue of £0.2 million, a decrease from £1.0 million in the prior year, and R&D costs rising to £1.9 million from £1.3 million, leading to a loss after tax of £3.0 million compared to £2.0 million. The company's cash reserves increased to £3.2 million from £1.9 million. Key developments include term sheet stage partnering discussions for an insulin-AID combination and continued progress on AT278 co-development. Post-period, Arecor announced a fundraising to raise up to £5.13 million.

Disclaimer*

UK 100

Latest directors dealings